Global Blood Therapeutics, Inc. focuses on developing innovative therapies for sickle cell disease, with its lead product, Oxbryta, gaining traction in the market. The company operates primarily in the United States, leveraging its unique expertise in hemoglobin modulation to differentiate itself from competitors.
Business Overview
GBT generates revenue primarily through the sale of Oxbryta, which is priced at approximately $10,000 per patient per year. The company benefits from a strong gross margin of 98.3%, indicating significant pricing power and a competitive advantage due to its specialized focus on sickle cell disease.
FDA approvals for new indications or therapies
Market penetration rates of Oxbryta
Partnerships or collaborations with larger pharmaceutical companies
Clinical trial results for pipeline products
Risk Factors
Regulatory changes impacting drug approval processes
Technological disruption in treatment methodologies
Emergence of alternative therapies for sickle cell disease
Increased competition from larger biotech firms with more resources
High debt-to-equity ratio (3.36) indicating potential liquidity issues
Negative operating cash flow impacting financial stability
Macro Sensitivity
low - The demand for sickle cell treatments is relatively inelastic, as they are essential for patients regardless of economic conditions.
Minimal impact, as the company is primarily focused on equity financing and does not rely heavily on debt for operations.
minimal
Profile
growth - Investors are likely attracted to the high revenue growth potential in a niche market.
high - The stock has shown significant volatility, as evidenced by a 124.9% return over the past year.
Explore More
Compare equities side by side
Stocks breaking to new annual highs
S&P 500 oversold value screener
Relative strength momentum leaders
Upcoming earnings dates & reports
Filter and sort all 500 stocks
Continuous multi-factor scoring & catalyst forensics
Today's biggest gainers and losers
